SEATTLE, Wash. and VANCOUVER, British Columbia, December 9, 2019 — Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced an update on the cytisinicline clinical development program. Following discussions with the Food and Drug Administration (FDA), Achieve…
/Read More
SEATTLE, Wash and VANCOUVER, British Columbia, November 6, 2019 — Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today provided an update on the cytisinicline clinical development program and announced third quarter 2019 financial results. Q3 2019 Highlights…
/Read More
SEATTLE, Wash. and VANCOUVER, British Columbia, October 31, 2019 — Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced that it will report its third quarter 2019 financial results on Wednesday, November 6, 2019. Company management will host a conference call and live webcast at 8:00am Eastern Time to report financial…
/Read More
SEATTLE, Wash. and VANCOUVER, British Columbia, October 24, 2019 — Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced that data from the Phase 2b ORCA-1 trial will be presented at the SRNT-O Inaugural Conference. “Successful Smoking…
/Read More
SEATTLE, Wash. and VANCOUVER, British Columbia, September 30, 2019 — Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation, today announced completion of their maximum tolerated dose (MTD) study. The results indicate a lack of dose-limiting toxicity as defined by protocol criteria…
/Read More